Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.

Socié G, Milpied N, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Lewalle P, Liens D, Mathis C, Guemas E, Vernant JP.

Blood Adv. 2019 Jan 22;3(2):184-186. doi: 10.1182/bloodadvances.2018028282. No abstract available.

2.

DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia.

Bond J, Touzart A, Leprêtre S, Graux C, Bargetzi M, Lhermitte L, Hypolite G, Leguay T, Hicheri Y, Guillerm G, Bilger K, Lhéritier V, Hunault M, Huguet F, Chalandon Y, Ifrah N, Macintyre E, Dombret H, Asnafi V, Boissel N.

Haematologica. 2019 Aug;104(8):1617-1625. doi: 10.3324/haematol.2018.197848. Epub 2019 Jan 17.

3.

Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

Le Bourgeois A, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, Orvain C, Wallet HL, Bilger K, Blaise D, Rubio MT, Guillaume T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Oncotarget. 2018 Nov 27;9(93):36603-36612. doi: 10.18632/oncotarget.26391. eCollection 2018 Nov 27.

4.

Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review.

Paix A, Antoni D, Waissi W, Ledoux MP, Bilger K, Fornecker L, Noel G.

Crit Rev Oncol Hematol. 2018 Mar;123:138-148. doi: 10.1016/j.critrevonc.2018.01.011. Epub 2018 Feb 8. Review.

PMID:
29482775
5.

Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord.

Nguyen S, Achour A, Souchet L, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Francois S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Lejeune J, Béziat V, Rocha V, Rio B, Chevret S, Vieillard V.

Bone Marrow Transplant. 2017 Oct;52(10):1428-1435. doi: 10.1038/bmt.2017.122. Epub 2017 Jun 26.

PMID:
28650455
6.

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.

Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P, Medeghri Z, Lehert P, Lai C, Corn T, Vernant JP.

Blood. 2017 Feb 2;129(5):643-649. doi: 10.1182/blood-2016-09-738625. Epub 2016 Nov 29.

7.

Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.

Hermet E, Cabrespine A, Guièze R, Garnier A, Tempescul A, Lenain P, Bouabdallah R, Vilque JP, Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Biron P, Legros L, Choufi B, Drenou B, Gorin NC, Bilger K, Tamburini J, Soussain C, Brechignac S, Bay JO; Société Française de Greffe de Moelle et de Thérapie Cellulaire.

J Geriatr Oncol. 2015 Sep;6(5):346-52. doi: 10.1016/j.jgo.2015.04.005. Epub 2015 Jun 23.

PMID:
26116168
8.

Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.

Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, Nagler A, Mohty M; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT).

Bone Marrow Transplant. 2015 Aug;50(8):1063-8. doi: 10.1038/bmt.2015.121. Epub 2015 Jun 1.

PMID:
26030052
9.

Understanding Nonurgent Pediatric Emergency Department Visits: Using Hospital and Family-Centric Data to Inform System Redesign.

Swavely D, Baker K, Bilger K, Zimmerman DF, Martin A.

J Nurs Care Qual. 2015 Oct-Dec;30(4):366-72. doi: 10.1097/NCQ.0000000000000126.

PMID:
26018565
10.

Raising awareness in your organization.

Bilger K.

Occup Health Saf. 2014 Oct;83(10):46-7. No abstract available.

PMID:
25980266
11.

Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

Rio B, Chevret S, Vigouroux S, Chevallier P, Fürst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Françoise S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Gluckman E, Ruggeri A, Buzyn A, Nguyen S, Simon T, Milpied N, Rocha V; Société Française de Greffe de Moelle et de Thérapie Cellulaire and Eurocord.

Biol Blood Marrow Transplant. 2015 Mar;21(3):445-53. doi: 10.1016/j.bbmt.2014.11.009. Epub 2014 Nov 18.

12.

Don't forget the lab.

Bilger K.

Occup Health Saf. 2014 Aug;83(8):43-4. No abstract available.

PMID:
25188995
13.

Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.

Chevallier P, Labopin M, Socié G, Tabrizi R, Furst S, Lioure B, Guillaume T, Delaunay J, de La Tour RP, Vigouroux S, El-Cheikh J, Blaise D, Michallet M, Bilger K, Milpied N, Moreau P, Mohty M.

Haematologica. 2014 Sep;99(9):1486-91. doi: 10.3324/haematol.2014.108563. Epub 2014 Jun 20.

14.

Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

Cahu X, Chevallier P, Clavert A, Suarez F, Michallet M, Vincent L, Vigouroux S, Blaise D, Mariette C, Bilger K, Robin M, Yakoub-Agha I, Peffault de Latour R, Mohty M.

Bone Marrow Transplant. 2014 Jun;49(6):756-60. doi: 10.1038/bmt.2014.31. Epub 2014 Mar 10.

PMID:
24614840
15.

Safety on ice.

Bilger K.

Occup Health Saf. 2013 Dec;82(12):18, 20. No abstract available.

PMID:
24417049
16.

Electrical safety basics: not exactly shocking.

Bilger K.

Occup Health Saf. 2013 Oct;82(10):48-9. No abstract available.

PMID:
24358643
17.

Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M.

Cancer. 2014 Mar 15;120(6):855-63. doi: 10.1002/cncr.28498. Epub 2013 Dec 10.

18.

Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Chevallier P, Labopin M, Milpied N, Bilger K, Socié G, Yakoub-Agha I, Michallet M, Bulabois CE, Maury S, Beguin Y, Bay JO, Blaise D, Maillard N, Guillerm G, Daguindeau E, Raus N, Mohty M.

Bone Marrow Transplant. 2014 Mar;49(3):361-5. doi: 10.1038/bmt.2013.186. Epub 2013 Dec 2.

PMID:
24292522
19.

[How to handle unexpected biological abnormalities observed in the pre-donation workup for hematopoietic stem cell transplantation: an SFGM-TC report on pre-transplant positive pregnancy test and monoclonal gammapathy].

Duléry R, Giraud C, Beaumont JL, Bilger K, Borel C, Dhedin N, Thiebaut A, Willems E, Alain S, Alfandari S, Dewilde A, Jouet JP, Milpied N, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):158-9. doi: 10.1016/j.patbio.2013.07.005. Epub 2013 Sep 4. French.

PMID:
24011965
20.

[How to handle unexpected biological abnormalities observed in the pre-donation workup for hematopoietic stem cell transplantation: an SFGM-TC report on pre-transplant cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, or syphilis IgM positive serology test].

Duléry R, Giraud C, Beaumont JL, Bilger K, Borel C, Dhedin N, Thiebaut A, Willems E, Alain S, Alfandari S, Dewilde A, Jouet JP, Milpied N, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):155-7. doi: 10.1016/j.patbio.2013.07.011. Epub 2013 Sep 4. French.

PMID:
24011960
21.

The more things change, the more they stay the same when your data shows a troublesome.

Bilger K.

Occup Health Saf. 2013 Jul;82(7):56-7. No abstract available.

PMID:
23951844
22.

Knowing what you need, using what you have.

Bilger K.

Occup Health Saf. 2013 May;82(5):14, 16, 18. No abstract available.

PMID:
23789545
23.

Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D, Tabrizi R, Clement L, Ceballos P, Daguindau E, Bilger K, Dhedin N, Lapusan S, Bay JO, Pautas C, Garban F, Ifrah N, Guillerm G, Contentin N, Bourhis JH, Yakoub Agha I, Bernard M, Cornillon J, Milpied N.

Haematologica. 2013 Sep;98(9):1467-75. doi: 10.3324/haematol.2012.080895. Epub 2013 Mar 28.

24.

Comfortably productive.

Bilger K.

Occup Health Saf. 2013 Feb;82(2):30, 32-33. No abstract available.

PMID:
23472340
25.

Tips for getting your message across.

Bilger K.

Occup Health Saf. 2012 Dec;81(12):16, 18. No abstract available.

PMID:
23304822
26.

Steering clear of driving program pitfalls.

Bilger K.

Occup Health Saf. 2012 Oct;81(10):30, 32. No abstract available.

PMID:
23094479
27.

A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm.

Gervais C, Dano L, Perrusson N, Hélias C, Jeandidier E, Galoisy AC, Ittel A, Herbrecht R, Bilger K, Mauvieux L.

Leukemia. 2013 Apr;27(5):1186-8. doi: 10.1038/leu.2012.286. Epub 2012 Oct 8. No abstract available.

PMID:
23041776
28.

Gaining traction on program success.

Bilger K.

Occup Health Saf. 2012 Jul;81(7):30, 32. No abstract available.

PMID:
22808864
29.

Sequential FDG PET and MRI findings in a case of human herpes virus 6 limbic encephalitis.

Hubele F, Bilger K, Kremer S, Imperiale A, Lioure B, Namer IJ.

Clin Nucl Med. 2012 Jul;37(7):716-7. doi: 10.1097/RLU.0b013e31824c5e2f.

PMID:
22691524
30.

Febrile pancytopenia as uncommon presentation of disseminated toxoplasmosis after BMT.

Bories P, Zink E, Mattern JF, Villard O, Berceanu A, Bilger K, Candolfi E, Herbrecht R, Abou-Bacar A, Lioure B.

Bone Marrow Transplant. 2012 Feb;47(2):301-3. doi: 10.1038/bmt.2011.62. Epub 2011 Mar 21. No abstract available.

PMID:
21423121
31.

Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO, Cahn JY, De Coninck E, Dhedin N, Bernard M, Rio B, Buzyn A, Huynh A, Bilger K, Bordigoni P, Contentin N, Porcher R, Socié G, Milpied N.

Br J Haematol. 2011 Feb;152(3):331-9. doi: 10.1111/j.1365-2141.2010.08417.x. Epub 2010 Dec 7.

PMID:
21133885
32.

[Occurrence of severe, persistent thrombocytopenia following allogeneic bone marrow transplantation, attributable to anti-HPA-1 allo-immunisation of the host].

Parissiadis A, Bilger K, Laplace A, Berceanu A, Schwebel M, Froelich N, Cazenave JP, Hanau D, Tourne S, Lioure B.

Transfus Clin Biol. 2010 Oct;17(4):265-8. doi: 10.1016/j.tracli.2010.07.002. Epub 2010 Oct 18. French.

PMID:
20961787
33.

Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.

Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, Pigneux A, Cornely OA, Ullmann AJ, Bofarull RM, de la Cámara R, Weisser M, Liakopoulou E, Abecasis M, Heussel CP, Pineau M, Ljungman P, Einsele H; Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation.

Haematologica. 2010 Oct;95(10):1762-8. doi: 10.3324/haematol.2009.020073. Epub 2010 Jul 15.

34.

Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V, Tabrizi R, Bulabois CE, Cacheux V, Kuentz M, Dreyfus B, Dreger P, Rio B, Moles-Moreau MP, Bilger K, Bay JO, Leblond V, Blaise D, Tournilhac O, Dhédin N.

Haematologica. 2010 Jun;95(6):950-5. doi: 10.3324/haematol.2009.017814. Epub 2010 Jan 15.

35.

EBV limbic encephalitis after allogenic hematopoietic stem cell transplantation.

Kremer S, Matern JF, Bilger K, Lioure B, Fornecker Y, Stoll-Keller F, Namer IJ, Dietemann JL, Fafi-Kremer S.

J Neuroradiol. 2010 Jul;37(3):189-91. doi: 10.1016/j.neurad.2009.10.001. Epub 2009 Dec 2.

PMID:
19959232
36.

Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I, Mohty M, Robin M, Tabrizi R, Clement L, Bilger K, Larosa F, Contentin N, Huyn A, François S, Bulabois CE, Ceballos P, Bourrhis JH, Buzyn A, Cornillon J, Guillerm G, de Revel T, Bay JO, Guilhot F, Milpied N.

Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85. doi: 10.1016/j.bbmt.2009.09.002. Epub 2009 Sep 8.

37.

Factors associated with overall and attributable mortality in invasive aspergillosis.

Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Amé S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat JP, Herbrecht R.

Clin Infect Dis. 2008 Nov 1;47(9):1176-84. doi: 10.1086/592255.

PMID:
18808352
38.

Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation.

Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D, Arnoulet C, Chabannon C, Vey N, Camerlo J, Bouabdallah R, Viens P, Maraninchi D, Bardou VJ, Esterni B, Blaise D.

Bone Marrow Transplant. 2005 Nov;36(10):901-6.

PMID:
16151421
39.

Single-agent thalidomide induces response in T-cell lymphoma.

Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M, Gastaut JA.

Eur J Haematol. 2005 Feb;74(2):169-71.

PMID:
15654910
40.

CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

Mohty M, Bagattini S, Chabannon C, Faucher C, Bardou VJ, Bilger K, Vey N, Gaugler B, Stoppa AM, Coso D, Ladaique P, Olive D, Viens P, Blaise D.

Exp Hematol. 2004 Nov;32(11):1097-102.

PMID:
15539088
41.

Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation.

Mohty M, de Lavallade H, Faucher C, Bilger K, Vey N, Stoppa AM, Gravis G, Coso D, Viens P, Gastaut JA, Blaise D.

Bone Marrow Transplant. 2004 Sep;34(6):527-30.

PMID:
15286687
42.

HSV excretion after bone marrow transplantation: a 4-year survey.

Morfin F, Bilger K, Boucher A, Thiebaut A, Najioullah F, Bleyzac N, Raus N, Bosshard S, Aymard M, Michallet M, Thouvenot D.

J Clin Virol. 2004 Aug;30(4):341-5.

PMID:
15163425
43.

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.

Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C, Perreau V, Bilger K, Coso D, Stoppa AM, Tabrizi R, Gastaut JA, Michallet M, Maraninchi D, Blaise D.

Bone Marrow Transplant. 2004 Jul;34(1):77-84.

PMID:
15133485
44.

Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level.

Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D, Arnoulet C, Chabannon C, Vey N, Camerlo J, Bouabdallah R, Maraninchi D, Bardou VJ, Blaise D.

Transfusion. 2004 Apr;44(4):501-8.

PMID:
15043564
45.

Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.

Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D, Sainty D, Gastaut JA, Viens P, Olive D, Gaugler B.

Bone Marrow Transplant. 2004 Apr;33(8):839-46.

PMID:
14767500
46.

Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient.

Damaj G, Ivanov V, Le Brigand B, D'incan E, Doglio MF, Bilger K, Faucher C, Vey N, Gastaut JA.

Ann Hematol. 2004 Jun;83(6):390-3. Epub 2003 Dec 10.

PMID:
14666380
47.

Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL.

Ivanov V, Faucher C, Bilger K, Vey N, Sainty D, Calmels B, Chabannon C, Lafage-Pochitaloff M, Mozziconacci MJ, Mohty M, Chrestian MA, Blaise D.

Bone Marrow Transplant. 2003 Nov;32(9):961-3. No abstract available.

PMID:
14562000
48.

Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen.

Faucher C, Mohty M, Vey N, Gaugler B, Bilger K, Moziconnacci MJ, Stoppa AM, Coso D, Ladaique P, Chabannon C, Reviron D, Maraninchi D, Gastaut JA, Olive D, Blaise D.

Exp Hematol. 2003 Oct;31(10):873-80.

PMID:
14550802
49.

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.

Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B, Cahn JY, Gratecos N, Sotto JJ, François S, Fleury J, Mohty M, Chabannon C, Bilger K, Gravis G, Viret F, Braud AC, Bardou VJ, Maraninchi D, Viens P.

Blood. 2004 Jan 15;103(2):435-41. Epub 2003 Aug 28.

50.

Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen.

Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Gastaut JA, Viens P, Maraninchi D, Olive D, Blaise D.

Leukemia. 2003 Nov;17(11):2168-77.

PMID:
12931226

Supplemental Content

Loading ...
Support Center